CTLA4 and autoimmune hepatitis: Exposure of PBMCs from patients with autoimmune liver diseases, including AIH, to very-low-dose Proleukin, used at less than 5 IU/ml, resulted in phosphorylation of STAT-5 and increased levels of CTLA-4 and FOXP3 in the Treg subset (107).